Yüklüyor......
Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
OBJECTIVE: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to examine the toxicity and response rates of weekly paclitaxel and carboplatin as...
Kaydedildi:
| Yayımlandı: | South Asian J Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Medknow Publications & Media Pvt Ltd
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4873699/ https://ncbi.nlm.nih.gov/pubmed/27275450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2278-330X.181629 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|